WO2011159926A1 - Agents antimicrobiens - Google Patents

Agents antimicrobiens Download PDF

Info

Publication number
WO2011159926A1
WO2011159926A1 PCT/US2011/040744 US2011040744W WO2011159926A1 WO 2011159926 A1 WO2011159926 A1 WO 2011159926A1 US 2011040744 W US2011040744 W US 2011040744W WO 2011159926 A1 WO2011159926 A1 WO 2011159926A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
compound
Prior art date
Application number
PCT/US2011/040744
Other languages
English (en)
Inventor
Edmond J. Lavoie
Ajit K. Parhi
Daniel S. Pilch
Original Assignee
Rutgers, The State University Of New Jersey
University Of Medicine And Dentistry Of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/039839 external-priority patent/WO2011156626A1/fr
Application filed by Rutgers, The State University Of New Jersey, University Of Medicine And Dentistry Of New Jersey filed Critical Rutgers, The State University Of New Jersey
Publication of WO2011159926A1 publication Critical patent/WO2011159926A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Definitions

  • MDR Multidrug Resistant
  • MRSA methicillin- resistant Staphylococcus aureus
  • Acinetobacter baumannii-calcoaceticus complex ABSC
  • MRSA methicillin- resistant Staphylococcus aureus
  • ABSC Acinetobacter baumannii-calcoaceticus complex
  • Elements of the bacterial cell division machinery present appealing targets for antimicrobial compounds because (i) they are essential for bacterial viability, (ii) they are widely conserved among bacterial pathogens, and (iii) they often have markedly different structures than their eukaryotic homologs.
  • One such protein that has been identified as a potential target is the FtsZ protein.
  • FtsZ During the division process, FtsZ, along with approximately 15 other proteins, assemble at mid-cell into a large cell division complex (termed the divisome), ultimately facilitating cell cytokinesis. More importantly, FtsZ is widely conserved among many bacterial strains. Summary of the Invention
  • the invention provides compounds that display antimicrobial activity. Accordingly, the invention provides a com ound of formula I:
  • R 1 , R 4 -R 8 , R 10 , R z -R >°6' , W, and A have the values defined in a), b), and c) below:
  • X is a counterion
  • A is N or CR 4' ;
  • R 4 , R 5 , R 2 , and R 3 is aryl substituted with one or more R cc and optionally substituted with one or more groups independently selected from (C 1 -C )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR g R h ; or at least one of R 4 , R 5 , R 2 , and R 3' is aryl substituted with one or more (Q-C ⁇ alkoxy and optionally substituted with one or more R ee ; or at least one of R 4 , R 5 , R 2 , and R 3 is heteroaryl substituted with one or more R dd and optionally substituted with one or
  • each aryl, and heteroaryl of R 4 , R 5 , R 2' , and R is optionally substituted with one or more groups independently selected from (d- C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 33 , -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR g R h ;
  • any adjacent R 6 , R 7 , R 8 , R 4 , and R 5 taken together can optionally be methylenedioxy and each remaining R 6 , R 7 , R 8 , R 4' , and R 5' is independently selected from H, R bb , and B-R x ;
  • each B is independently selected from -0-, -S-, and -N(R y )-;
  • R 6' is H, alkyl, halo, -NR e R f , N0 2 , aryl, heteroaryl, aryl(C r C 6 )alkyl, heteroaryl(d- C 6 )alkyl, aryl(d-C 6 )alkanoyl or heteroaryl(d-C 6 )alkanoyl wherein alkyl, aryl, heteroaryl, aryl(Ci-C 6 )alkyl, heteroaryl(C)-C6)alkyl, aryl(C 1 -C6)alkanoyl or heteroaryl(Ci-C6)alkanoyl are optionally substituted with one or more groups selected from halo, cyano, (C 1 -C 6 )alkyl, (C 3 - C 6 )cycloalkyl, carboxy, N0 2 , hydroxy, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxycarbon
  • R e and R f are each independently H, (Q-Ce ⁇ lkyl , aryl, heteroaryl, aryl(Ci-C 6 ) alkyl or heteroarylCQ-Ce) alkyl; or R e and R f together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
  • each R 8 and R h is independently selected from H, (Q-Ce ⁇ lkyl, (C3-C 6 )cycloalkyl, (C 3 - C6)cycloalkyl(Ci-C 6 )alkyl, aryl, heteroaryl, ary ⁇ C Ce) alkyl and heteroaryl(Ci-C 6 ) alkyl; or R 8 and R h together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R J is independently selected from H, (CrC 6 )alkyl, (C3-C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, ary ⁇ d-Ce) alkyl and heteroaryl(CrC )alkyl;
  • each R k is independently selected from H, (d-C )alkyl, (C3-C )cycloalkyl, (C 3 - C )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aryl(d-C6) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R u and R v is independently selected from H and (d-C 6 )alkyl
  • each R 32 is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (CrC6)alkoxy, (C 3 -C )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R bb is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (d-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R cc is independently selected from a) aryl that is substituted with one or more groups independently selected from (C]-C6)alkyl, halo, hydroxy, cyano, nitro, (d-C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 8 R h , -N(R j )S(0) 2 R k , and -NR 8 R h ; b) heteroaryl that is optionally substituted with one or more groups independently selected from (C!-C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 8 R h , -N(R j )S(0) 2 R k ,
  • each R ee is independently aryl that is optionally substituted with one or more groups independently selected from (CrC )alkyl, halo, hydroxy, cyano, nitro, (C]-C6)alkoxy, (C 3 - C 6 )cycloalkyl, carboxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R J )S(0) 2 R k , and -NR g R h ;
  • each R 68 and R 8 * 1 is independently selected from H, (C r C 6 )alkyl, (C3-C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, aryl, heteroaryl, ary ⁇ C Ce) alkyl and heteroaryl C Ce) alkyl; or R g and R h together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R hb is independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C )alkyl, aryl, heteroaryl, alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R hc and R hd is independently selected from H, (Ci-C6)alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, ary d-Ce) alkyl and heteroaryl(C 1 -C 6 ) alkyl; or R hc and R hd together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino; wherein any (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, ary d-Ce) alkyl or heteroaryl(C r C 6 )alkyl of
  • each R he is independently selected from H, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(CrC 6 )alkyl, aryl, heteroaryl, aryl(C ! -C6) alkyl and heteroaryl(Ci-C 6 )alkyl;
  • each R hm and R 1 " 1 is independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C C 6 )alkyl, aryl, heteroaryl, ary d-Ce) alkyl and heteroaryl(C C 6 ) alkyl; or R hm and R hn together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R kb is independently selected from H, (d-C ⁇ alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C]-C 6 )alkyl, aryl, heteroaryl, ary ⁇ d-Ce) alkyl and heteroaryl(Ci-C 6 )alkyl;
  • each R kc and R kd is independently selected from H, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C6)cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aryl(C !
  • each R ke is independently selected from H, (C 1 -C )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C )alkyl, aryl, heteroaryl, aryl(CrC 6 ) alkyl and heteroaryl(C !
  • each R 1 TM and R 101 is independently selected from H, (d-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aiyl(Ci-C 6 ) alkyl and heteroaryl(C C 6 ) alkyl; or R 1 TM and R 1 TM together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino; or b) the bond represented by— is present, R 10 is absent, and W is (NR 30 ) + D " except as defined below when R 30 and R 3a taken together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring or a 5- or 6-membered heteroaromatic ring;
  • R 4 , R 5 , R 2 , R 3 , and R 6 is selected from hydroxy, carboxy, cyano,
  • R 4 , R 5 , R 2' , R 3' , and R 6 are independently selected from hydrogen, halo, hydroxy, carboxy, cyano, CF 3 S0 3 -, (Q-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (d-C 6 )alkoxy, cycloalkyl, ary ⁇ C C ⁇ alkyl, aryl, heteroaryl, heteroary ⁇ Ci-C ⁇ alkyl, aryl(C
  • each (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C )alkynyl, (Cj- C 6 )alkoxy, cycloalkyl, and (C 1 -C6)alkanoyl of R 4 , R 5 , R 2 , R 3 , and R 6 is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C]-C 6 )alkoxy, cycloalkyl, oxo, carboxy, aryloxy, sulfo, -S(0) 2 NR 3g R 3h , -N(R j )S(0) 2 R 3k , and -NR 3g R 3h ; and wherein each aryl, and heteroaryl of R 4 , R 5 , R
  • any adjacent R 6 , R 7 , R 8 , R 4 and R 5 taken together can optionally be methylenedioxy and each remaining R 6 , R 7 , R 8 , R 4' and R 5 is independently selected from H, R 3bb , and Z-R 3x ;
  • A is N or C-R 4' ;
  • R 3a is hydrogen, (C 1 -C 6 )alkyl, aryl, aryl(C 1 -C 6 )alkyl, heteroaryl, or heteroaryliC
  • R b independently selected from halo, hydroxy, cyano, nitro, (CrC 6 )alkoxy, cycloalkyl, oxo, carboxy, -NR 3da R 3db , and aryloxy; and wherein each aryl, and heteroaryl of R b is optionally substituted with one or more groups independently selected from (Q-C ⁇ alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, carboxy, and aryloxy; or R 3a and R 3b taken together with the nitrogen to which they are attached form aziridino, azetidino, morpholino, piperazino, pyrrolidino, pyrrole, indole, or piperidino, which aziridino, azetidino, morpholino, piperazino, pyrrolidino pyrrole, indole, or piperidin
  • R 3c is hydrogen, (CrC 6 )alkyl, aryl, or heteroaryl;
  • each R 3k is independently selected from H, (C)-C6)alkyl, cycloalkyl, cycloalkyl(Ci- C 6 )alkyl, aryl, heteroaryl, aryl(CrC 6 ) alkyl and heteroaryl(C]-C 6 )alkyl;
  • each R 3p is independently selected from H, (Q-C ⁇ alkyl, cycloalkyl, cycloalky ⁇ Cr C 6 )alkyl, aryl, heteroaryl, aryl(CrC 6 ) alkyl and heteroaryl(C]-C )alkyl, wherein each aryl, and heteroaryl is optionally substituted with one or more groups independently selected from (C C )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3J )S(0) 2 R 3k , and -NR 3g R 3h ;
  • each R 3x is independently selected from (C]-C 6 )alkyl, (Q-Ce ⁇ lkanoyl, and
  • each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (CrC 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N
  • each R 4ce is independently selected from H, (C]-C 6 )alkyl, (C 3 -C )cycloalkyl, (C 3 - Ce ⁇ ycloalky ⁇ C C ⁇ alkyl, aryl, heteroaryl, aryl(Ci-C 6 ) alkyl and heteroaryl (d-C ⁇ alkyl;
  • heterocycle refers to a single saturated or partially unsaturated ring (e.g. 3, 4, 5, 6, 7 or 8-membered ring) from about 1 to 7 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the rings.
  • the sulfur and nitrogen atoms may also be present in their oxidized forms.
  • Such rings include but are not limited to azetidinyl, tetrahydrofuranyl or piperidinyl.
  • aryl(C 1 -C6)alkyl refers to a (C 1 -C 6 )alkyl radical in which one or more of the hydrogen atoms of the (C C )alkyl radical is replaced with an aryl radical.
  • heteroaryliC Ce) alkyl refers to a (Ci-C6)alkyl radical in which one or more of the hydrogen atoms of the radical is replaced with a heteroaryl radical.
  • an aryl(C 1 -C 6 )alkanoyl group refers to a group of the formula aryl-(Cjr C6)alkanoyl-, where aryl and (Q-C ⁇ alkanoyl are defined herein.
  • Such aryl(C 1 -C 6 )alkanoyl groups may include, but are not limited to, benzoyl, 4-phenylbenzoyl, and naphthoyl, and the like.
  • an heteroaryl(C]-C 6 )alkanoyl group refers to a group of the formula heteroaryl-(C ! -C )alkanoyl-, where heteroaryl and (C]-C 6 )alkanoyl are defined herein.
  • each B is independently selected from -0-, -S-, and -N(R y )-;
  • any aryloxy, or arylthio of R 14 is optionally substituted with one or more groups selected from halo, cyano, (d-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, carboxy, N0 2 , hydroxy, (d-C 6 )alkoxy, (Cj-C )alkoxycarbonyl, (C]-C 6 )alkanoyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, and -NR e R f ;
  • each R 8 and R h is independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C )cycloalkyl(CrC 6 )alkyl, aryl, heteroaryl, alkyl; or R 8 and R h together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino; each R j is independently selected from H, (Ci-C6)alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, aryl, heteroaryl, aryl(Ci-C ) alkyl and heteroaryl(Ci-C 6 )alkyl;
  • each R 33 is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C6)alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, (C3-C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R bb is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, (C3-C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R cc is independently selected from a) aryl that is substituted with one or more groups independently selected from (CrC 6 )alkyl, halo, hydroxy, cyano, nitro, (C C ⁇ alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR 8 R h ; or b) heteroaryl that is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, (C 3 -C6)cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k
  • each R dd is independently aryl or heteroaryl, which aryl or heteroaryl is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C )alkoxy, (C3-C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 8 R h , -N(R j )S(0) 2 R k , and -NR g R h ;
  • the invention provides a compound of formula (I) which is a compound of the following formula:
  • the invention provides a compound of formula (I) which is a compound of the following formula:
  • the invention provides a compound of formula (I) which is a compound of the following formula:
  • the invention provides a compound of formula (I) which is a compound of the following formula:
  • the invention provides a compound of formula (I) which is a compound of the following formula:
  • the invention provides a compound of formula (I) which is a compound of formula Ij :
  • the invention provides a compound of formula (I) which is a compound of formula Im:
  • the invention provides a compound of formula (I) which is a compound of formula Ip:
  • the invention provides a compound of formula (I) which is a compound of formula Ir:
  • At least one B is -0-.
  • At least one B is -S-.
  • At least one B is -N(R y )-.
  • R x is (Q-C ⁇ alkyl.
  • R 1 is cyano
  • R 1 is phenoxy
  • R 1 is -NR 3a R 3b .
  • R 1 is -NR 3a R 3b ;
  • R 3a is hydrogen or (C ⁇ - C 6 )alkyl; and
  • R 3b is (d-C 6 )alkyl that is substituted with one or more -NR 3da R 3db .
  • R 1 is -NR 3a R 3b ;
  • R 3a is hydrogen; and
  • R 1 is -NR 3a R 3b ;
  • R 3a is hydrogen; and
  • R 8 is (C ! -C 3 )alkoxy.
  • R 8 is methoxy
  • R 7 is (C 1 -C 3 )alkoxy.
  • R 7 is methoxy
  • R 6 is (C 1 -C 3 )alkoxy.
  • R 6 is methoxy
  • R 4' is (C!-C 3 )alkoxy.
  • R 4' is methoxy
  • R 5 is (C!-C 3 )alkoxy. In one specific embodiment of the invention R 5 is methoxy.
  • R 6 , R 7 , R 8 , R 4 and R 5 are each
  • R 6 , R 7 , R 8 , R 4 and R 5 are each methoxy. In one specific embodiment of the invention R 7 , R 8 , R 4 and R 5 are each methoxy.
  • R 4 and R 5 taken together are
  • R and R taken together are methylenedioxy and R 4 and R 5 taken together are methylenedioxy.
  • R 1 is methyl
  • At least one of R 4 , R 5 , R 2' and R 3' is aryl substituted with one or more R cc and optionally substituted with one or more groups
  • At least one of R 4 , R 5 , R 2' and R 3' is phenyl substituted with one or more R cc and optionally substituted with one or more groups
  • each R cc is aryl that is substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q- C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and - NR g R h .
  • each R cc is heteroaryl that is optionally substituted with one or more groups independently selected from (C 1 -C )alkyl, halo, hydroxy, cyano, nitro, (C C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR g R h .
  • each R cc is phenyl that is substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Cj- C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and - NR g R h .
  • each R cc is pyridyl or furyl that is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR 8 R h
  • At least one of R 4 , R 5 , R 2 and R 3 is heteroaryl substituted with one or more R dd and optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, (C 3 - C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 8 R h , -N(R j )S(0) 2 R k , and -NR g R h
  • At least one of R 4 , R 5 , R 2' and R 3' is pyridyl or furyl substituted with one or more R dd and optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (C]-C )alkoxy, (C 3 - C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h , -N(R j )S(0) 2 R k , and -NR g R h
  • At least one of R 4 , R 5 , R 2' , and R 3' is aryl(C,- C 6 )alkoxy.
  • At least one of R 4 , R 5 , R 2 , and R 3 is benzyloxy.
  • each R dd is independently aryl, which is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R dd is independently heteroaryl, which is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R dd is independently phenyl, which is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (CrC6)alkoxy, (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • each R dd is independently pyridyl or furyl, which pyridyl or furyl is optionally substituted with one or more groups independently selected from (C ! -C 6 )alkyl, halo, hydroxy, cyano, nitro, (C !
  • R 4 , R 5 , R 2' and R 3' is 4-(3- dimethylaminophenyl)phenyl, 2-phenyl-pyrid-5-yl, 2-(3-methoxyphenyl)pyrid-5-yl, 2-phenyl- furan-4-yl, 2-(pyrid-4-yl)pyrid-5-yl, 4-phenylpyrid-2-yl, 2,6-diphenylpyrid-4-yl, 3-phenylphenyl, or 3,5-diphenylphenyl.
  • the invention provides a compound of formula (I) which is:
  • the invention provides a compound of formula (I) which
  • the invention provides a compound of formula (I) wherein:
  • R 1 is -NR 3a R 3b or cyano
  • R 4 , R 5 , R 2 , R 3 , and R 6 is selected from hydroxy, carboxy, cyano,
  • R 4 , R 5 , R 2 , R 3' , and R 6 are independently selected from hydrogen, halo, hydroxy, carboxy, cyano, CF3SO3-, (Q-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C r C 6 )alkoxy, cycloalkyl, ary ⁇ C C ⁇ alkyl, aryl, heteroaryl, heteroaryl(C 1 -C 6 )alkyl, aryl(C 1 -C )alkanoyl, and heteroaryl(C 1 -C6)alkanoyl; wherein each (Q-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Q- C 6 )alkoxy,
  • each aryl, and heteroaryl of R 4 , R 5 , R 2 , R 3 , and R 6 is optionally substituted with one or more groups independently selected from (CrC ⁇ alkyl, halo, hydroxy, cyano, nitro, (d- C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ;
  • any adjacent R 6 , R 7 , R 8 , R 4 and R 5 taken together can optionally be methylenedioxy and each remaining R 6 , R 7 , R 8 , R 4' and R 5 is independently selected from H, R 3bb , and Z-R 3x ;
  • each Z is independently selected from -0-, -S-, and -N(R 3y )-;
  • R 30 is absent and D " is absent; or R 30 is H or (C 1 -C 6 )alkyl and D " is counterion;
  • R 30 and R 3a taken together with the atoms to which they are attached form a 5- or 6- membered heterocyclic ring or a 5- or 6-membered heteroaromatic ring, wherein a) when the bond represented by— is present in the 5- or 6-membered heterocyclic ring or the 5- or 6-membered heteroaromatic ring, then W is (NR ) D " and D " is a countenon, b) when the bond represented by — is absent in the 5- or 6-membered heterocyclic ring or the 5- or 6-membered heteroaromatic ring, then W is (NR 30 R 31 ) + D ' R 31 is (Ci-C 6 )alkyl and D " is a counterion, or c) when the bond represented by— is absent in the 5- or 6-membered heterocyclic ring or the 5- or 6-membered heteroaromatic ring, then W is (NR 30 );
  • A is N or C-R 4' ;
  • R 3a is hydrogen, (Cj-C 6 )alkyl, aryl, aryl(C 1 -C6)alkyl, heteroaryl, or heteroaryl(C ! - C 6 )alkyl; wherein each (CrC 6 )alkyl of R a is optionally substituted with one or more groups selected from halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, oxo, carboxy, and aryloxy, and wherein each aryl and heteroaryl of R 3a is optionally substituted with one or more groups selected from (Q-C ⁇ alkyl, halo, hydroxy, cyano, nitro, (C C )alkoxy, cycloalkyl, carboxy, and aryloxy; and R is hydrogen, (Ci-C 6 )alkyl, aryl, ary ⁇ Q-C ⁇ alkyl, heteroaryl, heteroaryl(d- C 6
  • R 3c is hydrogen, (C 1 -C 6 )alkyl, aryl, or heteroaryl;
  • R 3d is hydrogen, (Ci-C 6 )alk l, (Ci-C 6 )alkoxy, (Ci-C 6 )alkylthio, (C 1 -C 6 )alkanoyl, or - NR 3e R 3f ;
  • R 3e and R 3f are each independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, cycloalkyl(C!-C6)alkyl, aryl, heteroaryl, aryl(Ci-C6) alkyl and heteroaryl(C 1 -C 6 )alkyl; or R 3e and R 3f together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 3g and R 3h is independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl,
  • R 3g and R 3h together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 3 ⁇ 4 is independently selected from H, (C]-C 6 )alkyl, cycloalkyl, cycloalkyl(Cj- C 6 )alkyl, aryl, heteroaryl, arylCC Ce) alkyl and heteroaryl(C 1 -C6)alkyl;
  • each R 3k is independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, cycloalky ⁇ Q- C 6 )alkyl, aryl, heteroaryl, aryl(C ! -C 6 ) alkyl and heteroaryl(Ci-C 6 )alkyl;
  • each R 3m is independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, cycloalkyl(Ci- C 6 )alkyl, aryl, heteroaryl, aryl(C C6) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R 3n is independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, cycloalkyl(d- C 6 )alkyl, aryl, heteroaryl, aryl(C ! -C 6 ) alkyl and heteroaryl(C 1 -C 6 )alkyl, wherein each aryl, and heteroaryl is optionally substituted with one or more groups independently selected from (C ⁇ - C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-Ce ⁇ lkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ;
  • each R 3p is independently selected from H,
  • each R 3q is independently selected from H, (C 1 -C 6 )alkyl, cycloalkyl, cycloalkyl(Ci- C 6 )alkyl, aryl, heteroaryl, aryl(CrC 6 ) alkyl and heteroaryl(Ci-C 6 )alkyl; and each R 3r is independently selected from H, (C]-C 6 )alkyl, cycloalkyl, cycloalkyl(Ci-C 6 )alkyl, aryl, heteroaryl, aryliCj-Ce) alkyl and heteroaryl(d-C 6 )alkyl; or R 3q and R 3r together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino; each R 3u and R 3v is independently selected from H and (Q-C ⁇ alkyl;
  • each R 3x is independently selected from (C 1 -C6)alkyl, (Ci-C 6 )alkanoyl, and
  • each R 3y is independently selected from H and (Q-C ⁇ alkyl
  • each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and
  • each R 3bb is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h .
  • the invention provides a compound of formula (I) wherein:
  • R 6 R 7 , R 8 , R 4' and R 5 are each indepently selected from H and Z-R x ; or R 6 and R 7 taken together are methylenedioxy and R 8 , R 4 , and R 5 are each indepently selected from H and Z-R x ; or R 7 and R 8 taken together are methylenedioxy and R 6 R 4 and R 5 are each indepently selected from H and Z-R x ; or R 4 and R 5 taken together are methylenedioxy and R 6 R 7 , and R 8 are each indepently selected from H and -Z-R x ;
  • each Z is independently selected from -0-, -S-, and -N(R y )-;
  • R 4 , R 5 , R 2 , R 3 , and R 6 is selected from hydroxy, carboxy, cyano,
  • R 4 , R 5 , R 2 , R 3 , and R 6 are independently selected from hydrogen, hydroxy, carboxy, cyano, CF 3 S0 3 -, (Ci-C )s ky ⁇ , (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, aryl(C 1 -C 6 )alkyl, aryl, heteroaryl, heteroaryl(d-C 6 )alkyl, aryl(C
  • R 30 is absent and X " is absent; or R 30 is H or (d-C 6 )alkyl and X " is counterion;
  • R 11 is -NR 3a R 3b or cyano
  • R 3a is hydrogen, (Ci-C6)alkyl, aryl, arylCQ-C ⁇ alkyl, heteroaryl, or heteroary ⁇ C
  • R 3c is hydrogen, (C 1 -C 6 )alkyl, aryl, or heteroaryl;
  • R 3d is hydrogen, (C C 6 )alkyl, (Ci-C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C r C 6 )alkanoyl, or - NR 3e R 3f ;
  • R 3e and R 3f are each independently selected from H, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )cycloalkyl(C)-C 6 )alkyl, aryl, heteroaryl, ary ⁇ C Ce) alkyl and heteroaryl(C C )alkyl; or R e and R f together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 3g and R 3h is independently selected from H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C6)cycloalkyl(C(-C 6 )alkyl, aryl, heteroaryl, aryliQ-Ce) alkyl and heteroary ⁇ CrQ) alkyl; or R 3g and R 3b together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 3j is independently selected from H, (C 1 -C6)alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C]-C 6 )alkyl, aryl, heteroaryl, aryl(C ! -C 6 ) alkyl and heteroaryl(C!-C6)alkyl;
  • each R 3k is independently selected from H, (Ci-C6)alkyl, (C 3 -C )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aryl(Ci-C 6 ) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R 3m is independently selected from H, (Q-C ⁇ alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, arylCC Q) alkyl and heteroaryl(Cj-C 6 )alkyl;
  • each R 3n is independently selected from H, (C C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C - C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aryl(Ci-C6) alkyl and heteroaryl(CrC 6 )alkyl;
  • each R 3p is independently selected from H, (C C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C )alkyl, aryl, heteroaryl, ary ⁇ (C ⁇ -C ) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R 3q is independently selected from H, (Q-Ce ⁇ lkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C6)cycloalkyl(C C6)alkyl, aryl, heteroaryl, aryl(CrC 6 ) alkyl and heteroaryl(C 1 -C6)alkyl; and each R 3r is independently selected from H, (C 1 -C )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C6)alkyl, aryl, heteroaryl, aryl(C!-C 6 ) alkyl and heteroaryl(C!-C6)alkyl; or R 3q and R 3r together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 3u and R 3v is independently selected from H and (Ci-C6)alkyl
  • each R 3x is independently selected from (C 1 -C )alkyl, (C 1 -C 6 )alkanoyl, and
  • each R 3y is independently selected from H and (C]-C 6 )alkyl.
  • the invention provides a compound of formula (I) which is a compound of formula (Ilia):
  • R 6 is selected from hydroxy, carboxy, cyano, CF 3 S0 3 -, (Q-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C C 6 )alkoxy, cycloalkyl, aryl(Ci-C 6 )alkyl, aryl, heteroaryl, heteroaryl(C C 6 )alkyl, arylalkanoyl, and heteroarylalkanoyl; wherein each (Q-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 - C 6 )alkynyl, (Q-C ⁇ alkoxy, cycloalkyl, and (C C 6 )alkanoyl of R 6 is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C C 6 )alkoxy, cycloalkyl, o
  • the invention provides a compound of formula (I) which is a compound of formula (Illb):
  • R 3 is is selected from hydroxy, carboxy, cyano, CF3SO3-, (Ci-C6)alkyl, (C 2 -C 6 )alkenyl, (C2-C 6 )alkynyl, (Q-C ⁇ alkoxy, cycloalkyl, ary ⁇ C C ⁇ alkyl, aryl, heteroaryl, heteroaryltQ- C 6 )alkyl, arylalkanoyl, and heteroarylalkanoyl; wherein each (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 - C 6 )alkynyl, of R is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, oxo, carboxy, aryloxy, sulfo, -S(0) 2 NR 3g R 3h
  • the invention provides a compound of formula (I) which is a compound of formula (IIIc):
  • R 2' is selected from hydroxy, carboxy, cyano, CF 3 S0 3 -, (Q-Ceialkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, cycloalkyl, ary ⁇ C C ⁇ alkyl, aryl, heteroaryl, heteroaryliC C )alkyl, arylalkanoyl, and heteroarylalkanoyl; wherein each (C]-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 - C 6 )alkynyl, (d-C ⁇ alkoxy, cycloalkyl, and (C!-C6)alkanoyl of R 2 is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (CrC 6 )alkoxy, cycloalkyl,
  • the invention provides a compound of formula (I) which is a compound of formula (Hid):
  • R 4 is selected from hydroxy, carboxy, cyano, CF3SO3-, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (d-C )alkoxy, cycloalkyl, ary ⁇ d-C ⁇ alkyl, aryl, heteroaryl, heteroaryl(C !
  • each (d-C ⁇ alkyl, (C 2 -C 6 )alkenyl, (C 2 - C 6 )alkynyl, (d-C 6 )alkoxy, cycloalkyl, and (Ci-C 6 )alkanoyl of R 4 is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, oxo, carboxy, aryloxy, sulfo, -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and wherein each aryl, and heteroaryl of R 4 is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl,
  • the invention provides a compound of formula (I) which is a compound of formula (Hie):
  • R 5 is selected from hydroxy, carboxy, cyano, CF 3 S0 3 -, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C )alkynyl, (C!-C6)alkoxy, cycloalkyl, aryl(C 1 -C 6 )alkyl, aryl, heteroaryl, heteroaryltCr C 6 )alkyl, arylalkanoyl, and heteroarylalkanoyl; wherein each (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 - C 6 )alkynyl, (Ci-C6)alkoxy, cycloalkyl, and of R 5 is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cyclo
  • R is (C 1 -C 6 )alkyl and D " is counterion.
  • R is absent and D " is absent.
  • At least one Z is -0-.
  • At least one Z is -S-.
  • At least one Z is -N(R 3y )-.
  • each Z is -0-.
  • each Z is -S-.
  • each Z is -N(R 3y )-.
  • R 3x is (C 1 -C 6 )alkyl.
  • R 3a is hydrogen or methyl.
  • R is hydrogen, (C ⁇ -C )alky ⁇ , aryl, ary ⁇ Q- C 6 )alkyl, heteroaryl, or heteroaryl(C 1 -C 6 )alkyl.
  • R 3b is hydrogen, methyl, phenyl, or benzyl.
  • R 3a and R 3b taken together with the nitrogen to which they are attached form aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino, which aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino can optionally be substituted with one or more (Cj-C 6 )alkyl.
  • R 3c is hydrogen
  • R 3d is methyl or amino.
  • the invention provides a compound of formula (I) which is:
  • R 6 is selected from aryl and heteroaryl, which aryl, and heteroaryl of R 6 is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (CrC 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C !
  • R 3 is selected from aryl and heteroaryl, which aryl, and heteroaryl of R is optionally substituted with one or more groups independently selected from (Ci-C )alkyl, halo, hydroxy, cyano, nitro, (CrC )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 33 , -S(0) 2 NR 8 R h , -N(R j )S(0) 2 R k , and -NR 8 R h ; and each R 33 is
  • aryl and heteroaryl independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Cj-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR g R h ,
  • R is selected from aryl and heteroaryl, which aryl, and heteroaryl of R 2 is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-C6)alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 Rv k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C )alkyl, halo, hydroxy, cyano, nitro, (CrC 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S
  • R 4 is selected from aryl and heteroaryl, which aryl, and heteroaryl of R 4 is optionally substituted with one or more groups independently selected from (CrC 6 )alkyl, halo, hydroxy, cyano, nitro, (CrC )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo,
  • R 5 is selected from aryl and heteroaryl, which aryl, and heteroaryl of R 5 is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (C]-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -N 3 R g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (Q-C ⁇ alkyl, halo, hydroxy, cyano, nitro, (C C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -
  • R 6 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from (Q- C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C]-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Ci-C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0)
  • R is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from (Q- C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (Q-C ⁇ alkyl, halo, hydroxy, cyano, nitro, (C !
  • R is selected from aryl and heteroaryl, which aryl, and heteroaryl of R 2 is optionally substituted with one or more groups independently selected from (Ci-C 6 )alkyl, halo, hydroxy, cyano, nitro, (Q-Ce ⁇ lkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g3 R h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0)
  • R 4 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from (C]- C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (Ci-C6)alkyl, halo, hydroxy, cyano, nitro, (CrC 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2
  • R 5 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from (C C 6 )alkyl, halo, hydroxy, cyano, nitro, cycloalkyl, carboxy, aryloxy, nitro, sulfo, R 3aa , -S(0) 2 NR 3g R 3h , -N(R 3j )S(0) 2 R 3k , and -NR 3g R 3h ; and each R 3aa is independently selected from aryl and heteroaryl, which aryl and heteroaryl is optionally substituted with one or more groups independently selected from (C 1 -C 6 )alkyl, halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkoxy, cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 3g R 3h ,
  • R 6 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from phenyl, pyridyl, -NR 3g R 3h , (d-C 6 )alkoxy, dimethylaminophenyl, and halo.
  • R is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from phenyl, pyridyl, -NR 3g R 3h , (C 1 -C 6 )alkoxy, dimethylaminophenyl, and halo.
  • R 2 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from phenyl, pyridyl, -NR 3g R 3h , (d-C 6 )alkoxy, dimethylaminophenyl, and halo.
  • R 4 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from phenyl, pyridyl, -NR 3g R 3h , dimethylaminophenyl, and halo.
  • R 5 is selected from phenyl, pyridyl and furanyl and is optionally substituted with one or more groups independently selected from phenyl, pyridyl, -NR 3g R 3h , (C 1 -C 6 )alkoxy, dimethylaminophenyl, and halo.
  • At least one of R 4 , R 5 , R 2 , R 3 , and R 6 is selected from 3-biphenyl, 3-(4'-fluoro)biphenyl, 4-biphenyl, 4-(4'-fluoro)biphenyl, 3,5-bis(4- fluorophenyl)phenyl, 4-fluorophenyl, phenyl, 3-pyridyl, 4-pyridyl, 3-dimethylaminophenyl, 3- furanyl, 3-methoxyphenyl, 4-pyrid-3-ylphenyl, 4-pyrid-4-ylphenyl, 4-(3- dimethylaminophenyl)phenyl, 4-(3-furanyl)phenyl, 2-phenylpyrid-4-yl, 2-(3- methoxyphenyl)pyrid-3-yl, 2-phenylfur-4-yl, and 2-pyrid-4-yl)pyrid-5-y
  • A is N.
  • A is C-R 4 .
  • the invention provides a compound of formula (I) wherein:
  • R 4' , R 5' , R 6 , R 7 and R 8 are each indepently selected from H and Z-R 4x ; or R 4' and R 5 taken together are methylenedioxy and R 6 , R 7 , and R 8 are each indepently selected from H and Z-R 4x ; or R 7 and R 8 taken together are methylenedioxy and R 4 , R 5 , and R 6 are each indepently selected from H and Z-R 4x ; or R 6 and R 7 taken together are methylenedioxy and R 4 , R 5 , and R 8 are each indepently selected from H and -Z-R 4x ;
  • each Z is independently selected from -0-, -S-, and -N(R 4y )-;
  • R 2 , R 3 , R 4 , and R 5 is selected from hydroxy, carboxy, cyano, CF 3 S0 3 -, (d-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, aryl(C 1 -C 6 )alkyl, aryl, heteroaryl, heteroaryl(C 1 -C 6 )alkyl, arylalkanoyl, and heteroarylalkanoyl; and the remainder of R 2' , R 3' , R 4 , and R 5 are independently selected from H, hydroxy, carboxy, cyano, CF 3 S0 3 -, (d-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C
  • R 42 is H, (C C 6 )alkyl, aryl, heteroaryl, or aryl(C r C 6 )alkyl;
  • R 43 is H, (C C 6 )alkyl, aryl, heteroaryl, or aryl(C 1 -C 6 )alkyl;
  • R 1 is -NR a R b or cyano
  • R 4a is H, (C 1 -C 6 )alkyl, aryl, ary C C ⁇ alkyl, heteroaryl, or heteroarylCQ-C f alkyl;
  • each (Ci-C 6 )alkyl of R a is optionally substituted with one or more groups selected from halo, hydroxy, cyano, nitro, (C 3 -C 6 )cycloalkyl, oxo, carboxy, and aryloxy
  • each aryl and heteroaryl of R 4a is optionally substituted with one or more groups selected from (Cj-C )alkyl, halo, hydroxy, cyano, nitro, (Q-C ⁇ alkoxy, (C 3 -C6)cycloalkyl, carboxy, and aryloxy
  • R 4b is H, (CrC 6 )alkyl, aryl, aryl(C 1 -C 6 )alkyl, heteroaryl,
  • R 4c is H, (C ! -C 6 )alkyl, aryl, or heteroaryl;
  • R 4d is H, (d-C f alkyl, (d-C 6 )alkoxy, (CrC ⁇ alkylthio, (C C 6 )alkanoyl, or -NR e R f ;
  • R 4e and R 4f are each independently selected from H, (C 1 -C 6 )alkyl, (C3-C6)cycloalkyl, (C3-C 6 )cycloalkyl(C 1 -C 6 )alkyl, aryl, heteroaryl, aryl(CrC ) alkyl and heteroaryl(C C 6 )alkyl; or R 4e and R 4f together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 4g and R 4h is independently selected from H, (Q-C ⁇ alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, aryl, heteroaryl, ary ⁇ C Ce) alkyl and heteroary ⁇ Q-Ce) alkyl; or R 4g and R 4h together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 4j is independently selected from H, (Q-Ce ⁇ lkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C ⁇ cycloalky ⁇ CrC ⁇ alkyl, aryl, heteroaryl, a /l(C ⁇ -C ) alkyl and heteroaryl(C 1 -C6)alkyl;
  • each R 4k is independently selected from (Q-C ⁇ alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C6)alkyl, aryl, heteroaryl, arylCC Ce) alkyl and heteroaryl(C 1 -C6)alkyl;
  • each R 4m is independently selected from H, (CrC 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(CrC6)alkyl, aryl, heteroaryl, aryl(C!-C ) alkyl and heteroaryl(CrC 6 )alkyl;
  • each R 4n is independently selected from (C 1 -C )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C]-C 6 )alkyl, aryl, heteroaryl, aryl(C C6) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R 4p is independently selected from H, (Q-C ⁇ alkyl, (C 3 -C )cycloalkyl, (C 3 - C6)cycloalkyl(C!-C 6 )alkyl, aryl, heteroaryl, aryl(C!-C 6 ) alkyl and heteroaryl(C 1 -C 6 )alkyl;
  • each R 4q is independently selected from H, (C]-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(CrC 6 )alkyl, aryl, heteroaryl, aryliC Q) alkyl and heteroaryl(C 1 -C6)alkyl; and each R r is independently selected from H, (C !
  • R 4q and R 4r together with the nitrogen to which they are attached form a aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino;
  • each R 4s is independently trifiuoromethyl, trifluoromethoxy, or aryl optionally substituted with one or more (C 3 -C 6 )cycloalkyl, carboxy, aryloxy, nitro, sulfo, -S(0) 2 NR 4g R 4h , -N(R 4j )S(0) 2 R 4k , trifiuoromethyl,
  • each R 4u and 4 R V is independently selected from H and (C 1 -C 6 )alkyl
  • each R 4x is independently selected from (CirC 6 )alkyl
  • each R 4y is independently selected from H and (Q-C ⁇ alkyl; and W " is a counter anion;
  • the invention provides a compound of formula (I) which is a compound of formula (IVa):
  • the invention provides a compound of formula (I) which is a compound of formula (IVb):
  • the invention provides a compound of formula (I) which is a compound of formula (IVc):
  • the invention provides a compound of formula (I) which is a compound of formula (IVd):
  • the invention provides a compound of formula (I) which is a compound of formula (IVe):
  • the invention provides a compound of formula (I) which is a compound of formula (IVg):
  • the invention provides a compound of formula (I) which is a compound of formula (Ih):
  • At least one Z is -N(R y )-.
  • each Z is -N(R 4y )-.
  • R 4x is (CrC 6 )alkyl.
  • R 4 , R 5 , R 6 , and R 7 are each methoxy.
  • R 1 is -NR 4a R 4b .
  • R 4a is hydrogen or methyl.
  • R 4b is H, (Ci-C 6 )alkyl, aryl, aryl(Ci-C6)alkyl, heteroaryl, or
  • R 4b is H, methyl, phenyl, or benzyl.
  • R 4a and R 4b taken together with the nitrogen to which they are attached form aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino, which aziridino, azetidino, morpholino, piperazino, pyrrolidino or piperidino can optionally be substituted with one or more (C 1 -C 6 )alkyl.
  • R 4c is hydrogen
  • R 4d is methyl or amino
  • R 42 and R 43 are each H.
  • the invention provides a compound of formula (I) which is:
  • the invention provides a compound of formula (I) which
  • the invention provides a compound of formula (I) which is:
  • the invention provides a compound of formula (I) wherein R 1 , R 4 -R 8 , R 10 , R 2 -R 6 , W, and A have the values defined in a) and c).
  • the invention provides a compound of formula (I) wherein R 1 , R 4 -R 8 , R 10 , R 2 -R 6 , W, and A have the values defined in a).
  • the invention provides a compound of formula (I) wherein R 1 , R 4 -R 8 , R 10 , R ' -R 6' , W, and A have the values defined in b).
  • the invention provides a compound of formula (I) wherein R 1 , R 4 -R 8 , R 10 , R 2' -R 6' , W, and A have the values defined in c).
  • compounds of the invention including compounds of formula I set a), as well as synthetic intermediates that can be used for preparing compounds of formula I, can be prepared as illustrated in the following Schemes. It is understood that groups R ! -R 12 , W, Y, and Z shown in the Schemes below can represent the final groups present in a corresponding compound of formula I or that these groups can represent groups that can be converted to the final groups present in a corresponding compound of formula I at a convenient point in a synthetic sequence.
  • the groups R'-R 12 , W, Y, and Z can comprise one or more protecting groups that can be removed at a convenient point in a synthetic sequence to provide the corresponding final groups in the compound of formula I.
  • the substituted N-Boc protected benzylamine 20 can be converted to the dilithio 21 by treatment with two equivalents of sec-butyllithium. Acylation of dianion 21 can be
  • Beckmann rearrangement of a-ketooxime 29 with phosphorus pentachloride can produce 3-chloro-l(2H)isoquinolone 30 using literature methods.
  • Suzuki coupling of 30 with boronic acid 31 can afford the key compound 32.
  • Compound 32 can then be converted to triflate 33 which in turn can undergo a second Suzuki reaction with a boronic acid to afford compound 34.
  • Quarternization of 34 can then lead to compound 35.
  • Scheme 4 illustrates methods and intermediates that are useful for preparing R substituted compounds of the invention.
  • Scheme 6 illustrates methods and intermediates that are useful for preparing R 4 substituted compounds of the invention.
  • Scheme 7 illustrates methods and intermediates that are useful for preparing compounds are substituted at R 4 and R 3
  • Scheme 8 illustrates the preparation of an intermediate phenethylamine that is useful for preparing compounds of the invention.
  • Scheme 8a illustrates methods for the preparation of phenethylamine intermediates that have R 14 substituents.
  • the formation of ⁇ -substituted derivatives uses a nucleophile in a Michael addition reaction and the a-substituted derivatives is formed from a carbanion generated at the position adjacent to the nitro substituent, followed by reaction with an appropriate electrophile.
  • Scheme 9 illustrates methods and intermediates that are useful for preparing compounds of the invention.
  • Scheme 10 illustrates methods and intermediates that are useful for preparing R 7 substituted compounds of the invention.
  • Scheme 1 1 illustrates the preparation of isoquinoline intermediates that are useful for preparing compounds of the invention.
  • Scheme 12 illustrates the preparation of a triflate intermediate that is useful for preparing compounds of the invention.
  • Scheme 13 illustrates methods and intermediates that are useful for preparing R 3 substituted compounds of this invention.
  • Scheme 14 illustrates methods and intermediates that are useful for preparing R substituted compounds of the invention.
  • Scheme 15 illustrates methods and intermediates that are useful for preparing R substituted compounds of the invention.
  • Scheme 16 illustrates methods and intermediates that are useful for preparing R 3 substituted compounds of the invention.
  • Scheme 17 illustrates methods and intermediates that are useful for preparing substituted compounds of the invention.
  • Scheme 18 illustrates methods and intermediates that are useful for preparing R 5 substituted compounds of the invention.
  • Scheme 33 illustrates how intermediate chloro compound 3 can be used for preparing compounds of formula I.
  • Scheme 34 illustrates how intermediate chloro compounds 4 and 5 can be preparing.
  • Scheme 35 illustrates the preparation of a representative compound of the invention wherein R 30 and R 3a taken together with the atoms to which they are attached form a ring.
  • Scheme 36 illustrates the preparation of a representative compound of the invention wherein R 30 and R 3a taken together with the atoms to which they are attached form a ring.
  • Scheme 37 illustrates a method for the preparation of various 2-substituted 8-oxo-5,6- dihydro-3,10,1 l-trimethoxydibenzo[a,g]quinolizines that are useful intermediates for preparing compounds of formula I using appropriately substituted phenethylamines and 2-bromobenzoic acids.
  • Scheme 38 illustrates a method for the preparation of various 2-substituted 8-oxo-5,6- dihydro-3-methoxy-9,10-dimethylenedibenzo[a,g]quinolizines that are useful intermediates for preparing compounds of formula I using appropriately substituted phenethylamines and 2- bromobenzoic acids.
  • Scheme 39 illustrates a general method for the preparation of various 2-substituted-8- amino-5,6-dihydro-3, 10,l l-trimethoxydibenzo[(2,g]quinolizium and 2-substituted-8-cyano-5,6- dihydro-3, 10,1 l-trimethoxydibenzo[a,g]quinolizium compounds of formula I.
  • Scheme 40 illustrates the preparation of various 8-oxo-5,6-dihydro- dibenzo[a,g]quinolizines using appropriately substituted isoquinolin-l-ones and 1 -bromo-2-(2- bromoethyl)benzene intermediates.
  • Scheme 41 illustrates the preparation of various 8-oxo-5,6-dihydro- dibenzo[a,g]quinolizines using appropriately substituted isoquinolines and l-bromo-2-(2- bromoethyl)benzen derivatives.
  • the 8-oxo-5,6-dihydrodibeiizo[ ,g]quinolizme intermediates are useful intermediates for preparing compounds of formula I.
  • Scheme 42 illustrates general methods for preparing 8-oxo-5,6-dihydrodibenzo[a,g]- quinolizines that are useful for preparing compounds of formula I.
  • Scheme 43 illustrates methods for preparing 8-oxo-5,6-dihydrodibenzo[a,g]quinolizines that are useful for preparing compounds of formula I.
  • Scheme 44 illustrates a ring-closing metathesis method for preparing 8-oxo- dibenzo[a,g]quinolizine intermediates and their 5,6-dihydro analogs. These compounds are useful intermediates for preparing compounds of formula I.
  • Scheme 45 illustrates a method for preparing varied R 2 substituents of 8-oxo- dibenzo[a,g]quinolizines and 5,6-dihydro-8-oxo-dibenzo[a,g]quinolizines that can be converted into the corresponding 8-chloro dibenzo[a,g]quinolizinium compounds.
  • Scheme 46 illustrates a method for preparing varied R substituents of 8-oxo- dibenzo[a,g]quinolizines and 5,6-dihydro-8-oxo-diberizo[a,g]quinolizines that can be converted into the corresponding 8-chloro dibenzo[a,g]quinolizinium compounds.
  • Scheme 47 illustrates a method for preparing 8-oxo-dibenzo[a,g]quinolizines and 5,6-dihydro-8- oxo-dibenzo[a,g]quinolizines using an intramolecular Wittig-Horner reaction.
  • Scheme 48 illustrates a method for preparing 8-oxo-dibenzo[a,g]quinolizines and 5,6- dihydro-8-oxo-dibenzo[a,g]quinolizines that can ultimately be converted into the corresponding 8-chlorodibenzo[a,g]quinolizinium compounds.
  • the compounds of the present invention inhibit the ability of the protein to hydrolyze GTP.
  • This inhibition of FtsZ GTPase activity inhibits the ability of the protein to polymerize into Z-rings, as Z-ring formation requires GTP hydrolysis as an energy source for driving the reaction.
  • the Z-ring serves as the scaffold for recruitment of all other proteins that comprise the divisome complex, inhibition of Z-ring formation by the compounds of the present invention also results in a corresponding inhibition of divisome protein recruitment.
  • the compounds of the invention are useful to treat bacterial infections including infections by Gram-negative bacterial strains, Gram-positive bacterial strains and multiple drug- resistant bacterial strains
  • Gram-negative bacterial strains include Escherchia coli, Caulobacter crescentus, Pseudomonas aeruginosa, Agrobacterium tumefaciens, Branhamella catarrhalis, Citrobacter diversus, Enterobacter aerogenes, Enterobacter cloacae, Enterobacter sakazakii, Enterobacter asburiae, Pantoea agglomerans, Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella rhinoscleromatis, Proteus mirabilis, Salmonella typhimurium, Salmonella enteriditis, Serratia marcescens, Shigella sonnei, Neisseria gonorrhoeae, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter Iwoffi, Fusobacterium nucleatum, Veillonella parvula, Bacteroides forsythus, Act
  • Gram-positive bacterial strains include Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus pyogenes, Streptococcus faecalis, Enterococcus faecalis, Enterococcus faecium, Bacillus subtilis, Bacillus anthracis, Bacillus cereus, Micrococcus luteus, Mycobacterium tuberculosis, Clostridium difficile,
  • Propionibacterium acnes Streptococcus mutans, Actinomyces viscosus, Actinomyces naeslundii, Streptococcus sanguis, Streptococcus pneumoniae, Streptococcus viridans and Streptococcus salivarius.
  • Multiple drug-resistant bacterial strains include methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, multiple drug-resistant Mycobacterium tuberculosis, multidrug-resistant Clostridium difficile.
  • compounds of the present invention may be administered as a composition used to treat and/or prevent a bacterial infection wherein the bacterial cell uses polymerized FtsZ protein, or a homolog thereof, to facilitate cytokinesis.
  • compounds of the present invention may be administered to treat Staph Infections, Tuberculosis, Urinary Tract Infections, Meningitis, Enteric Infections, Wound Infections, Acne, Encephalitis, Skin Ulcers, Bed Sores, Gastric and Duodenal Ulcers, Eczema, Periodontal disease, Gingivitis, Halitosis, Anthrax, Tularemia, Endocarditis, Prostatitis, Osteomyelitis, Lyme Disease,
  • Pneumonia or the like.
  • compositions can, if desired, also contain other active therapeutic agents, such as a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an anti-cancer, other antimicrobial (for example, an aminoglycoside, an antifungal, an antiparasitic, an antiviral, a carbapenem, a cephalosporin, a flurorquinolone, a macrolide, a penicillin, a sulfonamide, a tetracycline, another antimicrobial), an anti-psoriatic, a corticosteriod, an anabolic steroid, a diabetes-related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium-related hormone, an antidiarrheal, an antitussive, an anti-emetic, an anti-ulcer, a
  • prodrug refers to any compound that when administered to a biological system (e.g. a mammal such as a human) generates the drug substance, i.e. active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s) or by some other process.
  • a prodrug is thus a modified (e.g. covalently modified) analog or latent form of a therapeutically- active compound.
  • a prodrug may also be an active metabolite or therapeutically-active compound itself.
  • a prodrug may generate the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, "Design and Application of Prodrugs” in A Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191; Tranoyl-Opalinski, I., Fernandes, A., Thomas, M., Gesson, J.-P., and Papot, S., Anti-Cancer Agents in Med. Chem., 8 (2008) 618-637).
  • Enzymes which are capable of an enzymatic activation mechanism with the prodrug compounds of the invention include, but are not limited to nitroreductase, proteases (e.g. serine proteases such as prostate specific antigen (PSA), amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and
  • proteases e.g. serine proteases such as prostate specific antigen (PSA), amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and
  • a salt of a compound of formula I can be useful as an intermediate for isolating or purifying a compound of formula I.
  • administration of a compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate.
  • pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • Salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording the corresponding anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording the corresponding anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • Pharmaceutically suitable counterions include pharmaceutically suitable cations and pharmaceutically suitable anions that are well known in the art.
  • pharmaceutically suitable anions include, but are not limited to those described above (e.g. physiologically acceptable anions) including CI “ , Br “ , ⁇ , CH 3 S0 3 " , CF 3 S0 3 " , /?-CH 3 C 6 H4 S0 3 " , citrate, tartrate, malate, fumarate, formate, or acetate.
  • a compound of the invention comprising a counterion can be converted to a compound of the invention comprising a different counterion.
  • Such a conversion can be accomplished using a variety of well known techniques and materials including but not limited to ion exchange resins, ion exchange chromatography and selective crystallization.
  • the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
  • the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluents, excipient or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
  • a pharmaceutically acceptable vehicle such as an inert diluents, excipient or an assimilable edible carrier.
  • the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 90% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations, particles, and devices.
  • the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, nanoparticles, and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • a suitable dose will be in the range of from about 0.1 to about 500 mg/kg, e.g., from about 0.5 to about 400 mg/kg of body weight per day, such as 1 to about 250 mg per kilogram body weight of the recipient per day.
  • the compound is conveniently formulated in unit dosage form; for example, containing 0.5 to 500 mg, 1 to 400 mg, or 0.5 to 100 mg of active ingredient per unit dosage form.
  • the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
  • Test A Determining the Impact of the Compounds of the Invention on FtsZ Polymerization Dynamics.
  • FtsZ polymerization dynamics can be tested using a light scattering-based competition binding assay using purified FtsZ.
  • FtsZ Upon addition of GTP, FtsZ self-associates to form polymeric structures that scatter light at 340 irai to a greater extent than the monomelic protein.
  • polymerization dynamics of FtsZ can be detected by an increase of decrease in the extent of GTP-induced light scattering relative to that observed in the absence of compound. Quantitation of the overall extent of light scattering at a given compound concentration provides an indication of the potency of that compound at altering FtsZ polymerization dynamics.
  • Test B can be determined using a method like Test B described below.
  • Test B Determining the FtsZ GTPase Inhibitory Activities of Compounds of the Invention.
  • Compound-induced inhibition of the FtsZ GTPase activity can be tested using a colorimetric assay in which the inorganic phosphate (Pi) released upon FtsZ-catalyzed hydrolysis of GTP reacts with malachite green and molybdate under acidic conditions to form a ternary complex that absorbs light at 650 nm, thus enabling quantitation of Pi levels by recording the absorbance at 650 nm (A650). All reactions are conducted in triplicate in 96-well microtiter plates.
  • Pi inorganic phosphate
  • Differing concentrations (ranging from 0 to 1.5 mM) of compound are combined with 1 mM GTP and 20 mM CaC12, the latter being used because FtsZ GTPase activity requires the presence of Ca2+ ions.
  • the reactions will be initiated by addition of 2 ⁇ FtsZ and allowed to incubate for 60 minutes at room temperature. Following incubation, the reactions will be stopped by adding 80 ⁇ of an acidic malachite green-molybdate solution containing 0.3 mg/ml malachite green oxalate, 2 mg/ml sodium molybdate, 0.5 mg/ml Triton X-100, and 0.7 N HC1.
  • each experiment includes reactions containing known concentrations (ranging from 0 to 10 ⁇ ) of monobasic potassium phosphate (KH2P04) in place of FtsZ.
  • KH2P04 monobasic potassium phosphate
  • a standard curve of A650 versus Pi concentration is constructed using the average A650 value obtained for each known KH2P04 concentration. This standard curve is then fit by linear regression analysis to yield the quantitative relationship between A650 and Pi concentration. The resulting relationship as well as the average A650 value for each test reaction is used to calculate the concentrations of Pi released by the GTPase activity of FtsZ.
  • the released Pi concentration in the absence of test compound is set as the mark for 100% GTPase activity, and is used to calculate the percent GTPase activities in reactions containing test compounds.
  • the percent GTPase activity is then plotted as a function of log(compund concentration), with the resulting curves being fit using an appropriate sigmoidal relationship to obtain the compound concentrations at which GTPase activity is inhibited by 50% (IC50 values). These IC50 values provide quantitative measures of the potencies with which the test compounds of the invention inhibit FtsZ GTPase activity. Results from Test B for representative compounds of the invention are shown in the following Table.
  • the antibacterial activity of a compound of the invention can be determined using methods like Test C and Test D described below.
  • Test C Planktonic (Free-Living) Antibacterial Assay.
  • Planktonic antibacterial activity can be determined using a broth microdilution assay in which log-phase bacteria are grown at 37 °C in appropriate medium containing two-fold serial dilutions of a compound to yield a final concentration ranging from 256 to 0.1 ⁇ g/ml.
  • MIC minimal inhibitory concentration
  • bacterial growth is monitored after 24 to 48 hours by measuring optical density at 600 nm.
  • MIC values reflect the minimal compound concentrations at which bacterial growth is completely inhibited.
  • the minimal inhibitory concentration against methicillin-Sensitive Staphylococcus aureus (MSSA) for each of the following representative compounds of the invention was determined to be less than 32 ⁇ g/ml. Data for representative compounds of the invention is provided below.
  • biofilms Bacteria growing in biofilms frequently exhibit altered sensitivities to antimicrobial agents relative to free-living bacteria. It is therefore important to assess the antibacterial activities of the compounds of the invention against bacteria growing as biofilms. Toward this end, well-established protocols can be used to determine biofilm susceptibilities to compounds.
  • the biofilms are prepared by seeding overnight cultures of bacteria on top of sterile polycarbonate membranes resting on Tryptic Soy Agar (TSA) plates. The plates are inverted and incubated for 48 hours at 37 °C. After 48 hours of incubation in the absence of antibiotic, colony biofilms are transferred to fresh TSA plates containing differing compound
  • biofilm eradication concentrations are defined by the minimum drug concentrations that eradicate the biofilm (i.e., minimum biofilm eradication concentrations, MBEC).
  • 3-Bromo-6,7-dimethoxyisoquinolin-l(2H)-one (100 mg) was combined with terphenyl boronic acid (193 mg, 2 eq.), Pd(0Ac) 2 (8 mg, 0.1 eq.), XPhos (33.5 mg, 0.2 eq.), and K2CO3 (194 mg, 4 eq.) in a flask and degassed. 6 mL ACN and 3 mL of H 2 0 were then added and solution was heated at 100°C for 1.5 hours. Reaction mixture was cooled to room temperature then diluted with EtOAc and washed with NaHC0 3 . Organic layer was dried over sodium sulfate and concentrated.
  • Guanidine HCl (13 mg, 3 eq.) was added to a suspension of NaH 60% dispersion in mineral oil (6 mg, 3 eq.) in 2 mL anhydrous DMSO. Reaction was heated at 60°C for 30 minutes then 3-([l,l'-biphenyl]-3-yl)-l-chloro-6,7-dimethoxyisoquinoline (20 mg) and chloro(2-di- t-butylphosphino-2', 4', 6'-tri-i-propyl-l,l'-biphenyl)[2-(2-aminoethyl)phenyl]PdII) (5 mg, 0.1 eq.) were then quickly added, and the reaction was heated at 100°C overnight.
  • 3-Bromo-6,7-dimethoxyisoquinolin-l(2H)-one (550 mg) was combined with 3-biphenyl boronic acid (768 mg, 2 eq.), Pd(OAc) 2 (43.5 mg, 0.1 eq.), XPhos (185 mg, 0.2 eq.), and K 2 C03 (1.07 g, 4 eq.) in a flask and degassed. 15 mL ACN and 7.5 mL of H 2 0 were then added and solution was heated at 100°C for 1.5 hours. Reaction mixture was cooled to room temperature then diluted with EtOAc and washed with NaHC0 3 . Organic layer was dried over sodium sulfate and concentrated.
  • Guanidine HCl (38 mg, 3 eq.) was added to a suspension of NaH 60% dispersion in mineral oil (10 mg, 3 eq.) in 5 mL anhydrous DMSO. Reaction was heated at 60°C for 30 minutes then 3-([l,l'-biphenyl]-3-yl)-l-chloro-6,7-dimethoxyisoquinoline (50 mg) and chloro(2-di- t-butylphosphino-2', 4', 6'-tri-i-propyl-l,l'-biphenyl)[2-(2-aminoethyl)phenyl]PdII) (9 mg, 0.1 eq.) were then quickly added, and the reaction was heated at 100°C overnight.
  • ethylenediamine was heated at 150 °C in a sealed tube overnight. Solution was then cooled to room temperature and concentrated. Chromatography achieved using silica column max gradient 10% MeOH/DCM/1% NH 4 OH yielding product as a beige oil (12 mg, 23% yield).
  • reaction mixture was diluted with CH2CI2 (100 mL) and washed with saturated NaHCC (50 ml), brine (50 mL), dried over Na 2 S04, concentrated in rotavapor and purified on silica gel. Elution with 20%
  • reaction mixture was diluted with CH2CI2 (30 mL) and washed with saturated NaHC0 3 (10 ml), brine (10 mL), dried over Na 2 S0 4 , concentrated in rotavapor and purified on silica gel. Elution with CH2CI2 afforded the title compound (150 mg, 37%) as a white solid.
  • reaction mixture was diluted with EtOAc (100 mL), washed with water (30 mL), 10% LiCl (30 mL), brine (30 mL), dried over Na 2 S0 4 , concentrated in rotavapor and purified on silica gel. Elution with 20%

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de formule I : ou un sel ou promédicament de celui-ci, où R1, R4 à R8, R10, R2' à R6', W, et A ont l'une quelconque des valeurs décrites dans la spécification, ainsi que des compositions comprenant un composé de formule I. Les composés sont utiles en tant qu'agents antibactériens.
PCT/US2011/040744 2010-06-16 2011-06-16 Agents antimicrobiens WO2011159926A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35540810P 2010-06-16 2010-06-16
US61/355,408 2010-06-16
US37275510P 2010-08-11 2010-08-11
US61/372,755 2010-08-11
USPCT/US2011/039839 2011-06-09
PCT/US2011/039839 WO2011156626A1 (fr) 2010-06-09 2011-06-09 Agents antimicrobiens

Publications (1)

Publication Number Publication Date
WO2011159926A1 true WO2011159926A1 (fr) 2011-12-22

Family

ID=45348550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040744 WO2011159926A1 (fr) 2010-06-16 2011-06-16 Agents antimicrobiens

Country Status (1)

Country Link
WO (1) WO2011159926A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080291A2 (fr) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
CN106674106A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种拓扑异构酶i抑制剂的合成方法
CN106674109A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种抗癌抑制剂中间体的合成方法
CN106674107A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种抗肿瘤药物化合物的合成方法
US9663520B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US11026926B2 (en) 2013-06-21 2021-06-08 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090076074A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20100120810A1 (en) * 2007-07-12 2010-05-13 Bertrand Leblond Compounds and methods for modulating rho gtpases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090076074A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
US20100120810A1 (en) * 2007-07-12 2010-05-13 Bertrand Leblond Compounds and methods for modulating rho gtpases
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080291A2 (fr) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2014080291A3 (fr) * 2012-11-21 2014-09-12 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9598367B2 (en) 2012-12-21 2017-03-21 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9861637B2 (en) 2012-12-21 2018-01-09 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
US10363257B2 (en) 2013-06-21 2019-07-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US11446306B2 (en) 2013-06-21 2022-09-20 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US11026926B2 (en) 2013-06-21 2021-06-08 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US9663520B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10772892B2 (en) 2013-06-21 2020-09-15 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10010556B2 (en) 2013-06-21 2018-07-03 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CN106674106A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种拓扑异构酶i抑制剂的合成方法
CN106674107A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种抗肿瘤药物化合物的合成方法
CN106674109A (zh) * 2016-12-15 2017-05-17 温州医科大学附属第二医院 一种抗癌抑制剂中间体的合成方法

Similar Documents

Publication Publication Date Title
WO2011156626A1 (fr) Agents antimicrobiens
WO2011159926A1 (fr) Agents antimicrobiens
US9227966B2 (en) Antimicrobial agents
US9102617B2 (en) Antimicrobial agents
US8563596B2 (en) Enantiomerically pure compounds for the treatment of proliferative disorders
WO2013106761A2 (fr) Agents antimicrobiens
US11826357B2 (en) Bacterial efflux pump inhibitors
US11938114B2 (en) Bacterial efflux pump inhibitors
JP2017537947A (ja) 抗生物質増強剤としての複素環化合物
CZ126899A3 (cs) Deriváty kyseliny piperidinketokarbonové, jejich použití a léčebný přípravek
WO2017147335A1 (fr) Inhibiteurs des pompe à efflux bactériennes
RU2129546C1 (ru) 6,9-бис(аминозамещенные)-бензо(g)изохинолин-5,10-дионы, способ их получения, фармацевтическая композиция на их основе и способ ингибирования опухолей у млекопитающих
KR102163608B1 (ko) 항균제
US9822108B2 (en) Antimicrobial agents
US10519098B2 (en) Aromatic derivatives as anti-malarial
KR0131999B1 (ko) 7-(4-아미노메틸-3-옥심)피롤리딘 치환제를 갖는 신규 퀴놀린 카르복실산 유도체 및 그의 제조방법
CN109705015B (zh) 组蛋白去乙酰化酶抑制剂及其制备方法与用途
RU2418786C2 (ru) Энантиомерно чистые производные флавона для лечения пролиферативных нарушений и способы их получения
JP2002527440A (ja) イミダゾ−イソキノリン化合物、その組成物、および使用
KR19980034828A (ko) 신규한 이소티아졸나프티리딘 유도체 및 그의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11796453

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11796453

Country of ref document: EP

Kind code of ref document: A1